Description: CorMedix Inc., a development stage pharmaceutical and medical device company, focuses on in-license, development, and commercialization of therapeutic products for the treatment of cardiac and renal dysfunction primarily in the dialysis and non-dialysis areas. It develops CRMD003 (Neutrolin), an antimicrobial/antifungal and anticoagulant combination in liquid formulation; and CRMD004, gel formulation of Neutrolin for the prevention of catheter-related blood stream infections and maintenance of catheter patency in hemodialysis patients. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.
Home Page: www.cormedix.com
CRMD Technical Analysis
300 Connell Drive
Berkeley Heights,
NJ
07922
United States
Phone:
908 517 9500
Officers
| Name | Title |
|---|---|
| Dr. Matthew T. David M.D. | Exec. VP & CFO |
| Dr. Phoebe Mounts Esq., Ph.D. | EVP, Gen. Counsel, Head of Regulatory, Compliance, Legal & Technical Operations and Sec. |
| Ms. Elizabeth Masson-Hurlburt B.A. | Exec. VP & Head of Clinical Operations |
| Mr. Joseph Todisco MBA | CEO & Director |
| Donna Ucci | Sr. VP & Head of Global Quality |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7711 |
| Price-to-Sales TTM: | 1837.6884 |
| IPO Date: | 2010-03-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |